Industry news that matters to you.  Learn more

Quest Diagnostics Expands Hereditary Cancer Screening Offering with Lynch Syndrome Blood and Biopsy Testing for Colorectal Cancer

Quest Diagnostics (NYSE: DGX), the world’s leading provider of diagnostic information services, recently announced new pathology and blood test offerings to help identify and assess an individual’s risk of Lynch syndrome, also known as hereditary nonpolyposis colorectal cancer (HNPCC), an inherited genetic disorder that significantly increases the risk of colorectal and other cancers.